ICU Medical Inc (ICUI)
155.59
+0.89
(+0.58%)
USD |
NASDAQ |
Dec 24, 12:45
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.810B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 57.92% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.616 |
| Price to Book Value | 1.860 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7783 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 68.82% |
Profile
| ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically. |
| URL | https://www.icumed.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically. |
| URL | https://www.icumed.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |